CardioFocus begins clinical trials on atrial fibrillation device
Courtesy | CardioFocus
Marlborough medical device manufacturer CardioFocus, Inc. has begun clinical trials of a new system to treat atrial fibrillation.
The HeartLight X3 System, according to the company’s announcement Monday, features many of the same technologies of the company’s previous devices, but is designed to deliver rapid, continuous, 360-degree lesions.
According to CardioFocus, the device treats atrial fibrillation, a cardiac rhythm disorder, by using laser energy to create lines of scar tissue to block abnormal electrical pathways causing the irregular heartbeat.
The new system’s ability to create those scar tissues at a rapid pace can help reduce procedure time, the company said.
In a statement, CardioFocus Chief Operating Officer Burke Barrett said the HeartLight X3 has the potential to reduce the procedure time by three times what it usually takes.
Initial cases were completed at Na Homolce Hospital in Prague, Czech Republic.
In a statement, Na Homolce Hospital Department of Cardiology head Petr Neuzil said the device can help reduce procedure times for pulmonary vein isolation.
"The potential reduction in procedure times combined with a better assurance of gap-free lesion sets will help this device change the way PVI is performed," he said.
Clinical evaluations are expected to continue through 2018.
WBJ Web Partners
Most Recent
Most Recent
0 Comments